When was Nereid founded?

Nereid was founded in 1999 and raised its 1st funding round 21 years after it was founded.

Where is Nereid located?

Nereid is headquartered in Cambridge, United States. It is registered at 451 D Street Suite 912 Boston, MA 02210.

How many employees does Nereid have?

As of Jun 30, 2026, the latest employee count at Nereid is 2.

Is Nereid a funded company?

Nereid is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Nov 23, 2020.

When was the latest funding round of Nereid?

Nereid's latest funding was a $***** Series A round on Nov 23, 2020, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $3.47B in funding in 2026 to date.

Where does Nereid rank among its competitors?

Nereid ranks 2916th amongst 3629 active competitors, of which 1249 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Nereid?

Nereid's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Nereid - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of small molecule drugs to treat cancers, neurodegenerative, and inflammatory diseases. The company developed small molecule therapeutics based on liquid-liquid phase separation (LLPS). The company uses its proprietary microscopy, computer vision, and machine learning technology to develop drugs that can modulate protein interactions found in disease states. LLPS occurs in living cells that help in the formation and function of membrane-less compartments which is responsible for gene regulation in diseased-state. processes.

Website: nereidtx.com
Email ID: *****@nereidtx.com
Phone Number: +1 **********
Part Of
Registered Address: 451 D Street Suite 912 Boston, MA 02210

Key Metrics

Founded Year

1999

Location

Cambridge, United States

Stage

Series A

Total Funding

$50M in 1 round

Latest Funding Round

Series A, Nov 23, 2020, $*****

Investors

Apple Tree Partners

Ranked

2916^th among 3629 active competitors

Employee Count

2 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3428 more

View Nereid's full profile

Nereid is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
NEREID THERAPEUTICS INCORPORATED CIN: 85-3368493 , United States, Active	Oct 05, 2020	-	5 (As on Dec 31, 2021)	-

Nereid has raised a total funding of $50M over 1 round. Its latest funding round was a Series A round on Nov 23, 2020 for $*****. 1 investor participated in its latest round. Nereid has 1 institutional investor.

Here is the list of recent funding rounds of Nereid:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 23, 2020	2466486	Series A	8295546	8431846	7209737	2261840

Access funding benchmarks and valuations. Sign up today!

View details of Nereid's funding rounds and investors

The founders of Nereid is Cliff Brangwynne.

Here are the details of Nereid's key team members:

Cliff Brangwynne: Co-Founder of Nereid.

View details of Nereid's Founder profiles and Board Members

Nereid's employee count trend

Nereid has 2 employees as of Jun 26. Here is Nereid's employee count trend over the years:

Uncover Nereid's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Nereid include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Nereid, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
2916th	Nereid 1999, Cambridge (United States), Series A	Developer of small molecule drugs to treat cancers, neurodegenerative, and inflammatory diseases	$50M	Apple Tree Partners	23/100